Developer docs
API playgroundTry for free, no card

Search company profiles

Solaxa

Full company profile

uuid0003fli

Namestring
Solaxa
Legal namestring
Solaxa Inc.
Websiteurl
solaxa.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Solaxa Inc. is a clinical-stage biopharmaceutical company founded in 2021 (originally as Peripheral Therapeutics Inc.) and headquartered in Bethesda, Maryland, operating as a Delaware Public Benefit Corporation. It is developing proprietary reformulations of aminopyridine ion-channel modulators to detect and treat nerve dysfunction, with a lead asset SLX-100 — a uniquely formulated dalfampridine (4-aminopyridine) — being advanced for spinocerebellar ataxia type 27B (SCA27B), a rare neurodegenerative disease with no FDA-approved therapies. The underlying science originates from co-founders Mark Noble (University of Rochester, founding scientific advisor to Acorda Therapeutics) and John Elfar (University of Arizona), and the broader aminopyridine platform is also being explored for traumatic peripheral nerve injury diagnosis and chemotherapy-induced neuropathy.

Solaxa operates in a capital- and partnership-intensive model typical of rare-disease biotech. It has secured FDA Orphan Drug Designation for 4-aminopyridine in SCA (7-year market exclusivity upon approval), FDA IND clearance via the Section 505(b)(2) pathway, and a registrational Phase 3 trial funded in part by a $7.3 million Congressionally Directed Medical Research Program grant. Its go-to-market strategy is asset-centric and out-licensed: in February 2026 it signed a $95 million global licensing agreement with Alvogen for SLX-100 in SCA27B, under which Alvogen (via its Almatica CNS subsidiary) handles worldwide commercialization while Solaxa retains regulatory sponsorship and is eligible for upfront, development, regulatory, and sales milestone payments plus double-digit royalties. Direct revenue from product sales is not contemplated; revenue mechanics are licensing, milestone, and royalty income.

Funding to date has been modest but strategically staged: a $670,000 round (May 2024), a $500,000 TEDCO/SSBCI investment (July 2024), and non-dilutive grant funding channeled through academic partners such as UCLA and Penn State. Leadership has been built out with Kerry Clem (formerly CCO of Acorda, now CEO), Amy Chappell, MD, FAAN as CMO (ex-Eli Lilly), Luis Gutierrez as COO, and Pete Zaudtke as Head of Business Development, alongside founder Christian Walker. Headcount is reported at 1-10, consistent with a lean clinical-stage operation that outsources clinical execution and, post-Alvogen, commercialization.

Short descriptiontext

Solaxa Inc. is a Bethesda-based clinical-stage biopharmaceutical company developing proprietary aminopyridine drugs, led by SLX-100 for spinocerebellar ataxia type 27B (SCA27B), with commercialization rights out-licensed to Alvogen via a $95 million agreement.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBethesda, United States
HQ citystring
Bethesda
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, aminopyridine therapeutics, nerve function restoration, rare neurological disease drugs, ion channel modulators
Industry4 codes
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Disease Neurology Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Solaxa receives upfront payments, development milestones, regulatory milestones, and sales-based milestone payments from partners. The Alvogen agreement provides for an upfront payment plus up to $95 million in aggregate milestone payments, plus double-digit royalties on net sales.

solaxa.com
2Drug Development and Commercialization
TypeHardware Sales
Description

Pre-commercial clinical stage company developing proprietary formulations of aminopyridine drugs. Revenue expected from future product sales following FDA approval.

solaxa.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Solaxa develops proprietary aminopyridine-based drug candidates — most notably SLX-100, a reformulated dalfampridine (4-aminopyridine) — to detect and treat nerve dysfunction in rare neurodegenerative and traumatic nerve disorders such as spinocerebellar ataxia type 27B (SCA27B), hereditary ataxias, peripheral nerve injury, and chemotherapy-induced peripheral neuropathy. The company advances these candidates through FDA clinical and regulatory milestones and monetizes them via out-licensing to commercial partners rather than direct sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Significant clinical improvement in gait, balance, and speech observed in patients with spinocerebellar ataxias
+1 more record
Product overview1 text field

Solaxa is a clinical-stage biopharmaceutical company developing a focused portfolio of aminopyridine-based drugs that detect and treat ion channel dysfunction to restore nerve function. The company's primary product is SLX-100, a reformulated dalfampridine (4-aminopyridine) treatment for spinocerebellar ataxia type 27B (SCA27B) which achieved FDA IND clearance in January 2025 and entered Phase 3 clinical trials in March 2025. The pipeline targets hereditary ataxias, traumatic nerve injury, and chemotherapy-induced neuropathy. The company operates as a Public Benefit Corporation focused on developing accessible and impactful treatments.

Product and service1 record
1SLX-100
CategoryClinical-stage neurology pharmaceutical (orphan drug)
Description

SLX-100 is Solaxa's lead clinical-stage drug candidate — a proprietary reformulation of dalfampridine (4-aminopyridine) designed to modulate voltage-gated potassium ion channels and detect and treat nerve damage. It is being developed under the FDA Section 505(b)(2) pathway for spinocerebellar ataxia type 27B (SCA27B), a hereditary ataxia with no FDA-approved therapy, and is the subject of a $95M worldwide licensing deal with Alvogen (February 2026). The asset is intended for rare-disease neurology patients and is partnered to Alvogen's CNS-focused subsidiary Almatica for commercialization.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-23
Description

Global license agreement for development and commercialization of SLX-100 for spinocerebellar ataxia type 27B. Alvogen acquires worldwide rights and will commercialize in U.S. through its Almatica CNS subsidiary and globally. Solaxa eligible for $95M in aggregate milestone payments plus double-digit royalties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-28
Description

Partnership with Dr. Susan Perlman at UCLA for registrational clinical trial of SLX-100 for SCA27B. Funded by $7.3M Congressionally Directed Medical Research Program grant.

3National Ataxia Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-25
Description

Sponsored research agreement including participation in NAF's Drug Development Collaborative, sponsorship of CRC-SCA natural history study expansion to include SCA27B, and sponsorship of free genetic testing program for SCA27B diagnosis.

solaxa.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-24
Description

Clinical trial collaboration evaluating 4-aminopyridine for diagnosing peripheral nerve injury type. Dr. John Elfar's team at CORTS conducting NIH-funded study to determine whether nerves are severed or crushed in trauma patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding scientific collaboration with Mark Noble, Ph.D., Professor of Biomedical Genetics and Neuroscience at University of Rochester, who serves as CSO and Co-Founder. Technology based on discoveries from his lab.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding scientific collaboration with John Elfar, M.D., MBA, Professor and Chair of Orthopedics at University of Arizona, who serves as scientific advisor. His research on 4-AP for nerve injury diagnosis underlies company technology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Original developer of branded dalfampridine (Ampyra/4-AP) approved for MS walking impairment; the same active ingredient Solaxa is reformulating for SCA27B. Acorda's commercialization history underpins Solaxa's strategic playbook.

TypeDirect peer
Description

Rare neurology-focused biopharma developing therapies for serious neurological diseases, now part of Biogen. Comparable in clinical-stage development and orphan disease commercialization.

TypeDirect peer
Description

Specialty pharma focused on rare neurological and ophthalmic diseases with orphan-drug commercialization expertise. Comparable in targeting rare CNS indications with high unmet need.

TypeDirect peer
Description

CNS-focused commercial-stage company that licensed and commercialized a neurology asset (Wakix). Comparable in licensing-driven model and rare neurology commercialization.

TypeDirect peer
Description

Clinical-stage biotech developing therapies for rare neurodegenerative diseases including Friedreich's ataxia. Direct comparator in rare ataxia/neurodegenerative space.

TypeEmerging player
Description

Clinical-stage company targeting severe genetic neurological diseases using antisense oligonucleotide technology. Overlaps in rare neurology with similar clinical-stage profile.

TypeEmerging player
Description

Clinical-stage company developing treatments for rare lysosomal storage disorders with neurological involvement. Comparable as emerging rare neurology biotech.

TypeBroad incumbent
Description

CNS-focused biopharma with broad neurology pipeline. Comparable as a CNS-focused specialty pharma that has successfully licensed and commercialized rare neurology assets.

TypeBroad incumbent
Description

CNS-focused biopharma developing therapies for neurological and psychiatric disorders. Comparable as a broader CNS biopharma with orphan-drug experience and licensing-driven commercialization.

TypeEmerging player
Description

Specialty pharma with reformulation expertise in CNS indications via proprietary drug delivery platforms. Comparable to Solaxa's reformulation-driven 505(b)(2) strategy for CNS.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Solaxa

Rare Disease Neurology Pharmaceuticalssolaxa.com

Solaxa Inc. is a Bethesda-based clinical-stage biopharmaceutical company developing proprietary aminopyridine drugs, led by SLX-100 for spinocerebellar ataxia type 27B (SCA27B), with commercialization rights out-licensed to Alvogen via a $95 million agreement.

What Solaxa does

Solaxa Inc. is a clinical-stage biopharmaceutical company founded in 2021 (originally as Peripheral Therapeutics Inc.) and headquartered in Bethesda, Maryland, operating as a Delaware Public Benefit Corporation. It is developing proprietary reformulations of aminopyridine ion-channel modulators to detect and treat nerve dysfunction, with a lead asset SLX-100 — a uniquely formulated dalfampridine (4-aminopyridine) — being advanced for spinocerebellar ataxia type 27B (SCA27B), a rare neurodegenerative disease with no FDA-approved therapies. The underlying science originates from co-founders Mark Noble (University of Rochester, founding scientific advisor to Acorda Therapeutics) and John Elfar (University of Arizona), and the broader aminopyridine platform is also being explored for traumatic peripheral nerve injury diagnosis and chemotherapy-induced neuropathy.

Solaxa operates in a capital- and partnership-intensive model typical of rare-disease biotech. It has secured FDA Orphan Drug Designation for 4-aminopyridine in SCA (7-year market exclusivity upon approval), FDA IND clearance via the Section 505(b)(2) pathway, and a registrational Phase 3 trial funded in part by a $7.3 million Congressionally Directed Medical Research Program grant. Its go-to-market strategy is asset-centric and out-licensed: in February 2026 it signed a $95 million global licensing agreement with Alvogen for SLX-100 in SCA27B, under which Alvogen (via its Almatica CNS subsidiary) handles worldwide commercialization while Solaxa retains regulatory sponsorship and is eligible for upfront, development, regulatory, and sales milestone payments plus double-digit royalties. Direct revenue from product sales is not contemplated; revenue mechanics are licensing, milestone, and royalty income.

Funding to date has been modest but strategically staged: a $670,000 round (May 2024), a $500,000 TEDCO/SSBCI investment (July 2024), and non-dilutive grant funding channeled through academic partners such as UCLA and Penn State. Leadership has been built out with Kerry Clem (formerly CCO of Acorda, now CEO), Amy Chappell, MD, FAAN as CMO (ex-Eli Lilly), Luis Gutierrez as COO, and Pete Zaudtke as Head of Business Development, alongside founder Christian Walker. Headcount is reported at 1-10, consistent with a lean clinical-stage operation that outsources clinical execution and, post-Alvogen, commercialization.

Solaxa firmographics

Firmographics
Name
Solaxa
Legal name
Solaxa Inc.
Website
https://solaxa.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Solaxa Inc. is a Bethesda-based clinical-stage biopharmaceutical company developing proprietary aminopyridine drugs, led by SLX-100 for spinocerebellar ataxia type 27B (SCA27B), with commercialization rights out-licensed to Alvogen via a $95 million agreement.
Ownership category
akta.pro rank

Solaxa industry classification

Industry
Product category
Rare Disease Neurology Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical-stage biopharmaceuticals
  • Aminopyridine therapeutics
  • Nerve function restoration
  • Rare neurological disease drugs
  • Ion channel modulators

Where Solaxa is headquartered

Location

Headquarters

HQ city
Bethesda
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Solaxa business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Milestone Payments: Solaxa receives upfront payments, development milestones, regulatory milestones, and sales-based milestone payments from partners. The Alvogen agreement provides for an upfront payment plus up to $95 million in aggregate milestone payments, plus double-digit royalties on net sales.
  2. Drug Development and Commercialization: Pre-commercial clinical stage company developing proprietary formulations of aminopyridine drugs. Revenue expected from future product sales following FDA approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Solaxa product offering

Product offering

Core offering

Solaxa develops proprietary aminopyridine-based drug candidates — most notably SLX-100, a reformulated dalfampridine (4-aminopyridine) — to detect and treat nerve dysfunction in rare neurodegenerative and traumatic nerve disorders such as spinocerebellar ataxia type 27B (SCA27B), hereditary ataxias, peripheral nerve injury, and chemotherapy-induced peripheral neuropathy. The company advances these candidates through FDA clinical and regulatory milestones and monetizes them via out-licensing to commercial partners rather than direct sales.

Product overview

Solaxa is a clinical-stage biopharmaceutical company developing a focused portfolio of aminopyridine-based drugs that detect and treat ion channel dysfunction to restore nerve function. The company's primary product is SLX-100, a reformulated dalfampridine (4-aminopyridine) treatment for spinocerebellar ataxia type 27B (SCA27B) which achieved FDA IND clearance in January 2025 and entered Phase 3 clinical trials in March 2025. The pipeline targets hereditary ataxias, traumatic nerve injury, and chemotherapy-induced neuropathy. The company operates as a Public Benefit Corporation focused on developing accessible and impactful treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • SLX-100 SLX-100 is Solaxa's lead clinical-stage drug candidate — a proprietary reformulation of dalfampridine (4-aminopyridine) designed to modulate voltage-gated potassium ion channels and detect and treat nerve damage. It is being developed under the FDA Section 505(b)(2) pathway for spinocerebellar ataxia type 27B (SCA27B), a hereditary ataxia with no FDA-approved therapy, and is the subject of a $95M worldwide licensing deal with Alvogen (February 2026). The asset is intended for rare-disease neurology patients and is partnered to Alvogen's CNS-focused subsidiary Almatica for commercialization.

Quantifiable outcome

  • Significant clinical improvement in gait, balance, and speech observed in patients with spinocerebellar ataxias
  • +1 more outcomes

Companies that use Solaxa

Customer profile

Segments2 records

Ideal customer profiles2 records

Solaxa technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Solaxa partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • AlvogencoreChannel Partner/ Reseller/ Distributor · 23 February 2026Global license agreement for development and commercialization of SLX-100 for spinocerebellar ataxia type 27B. Alvogen acquires worldwide rights and will commercialize in U.S. through its Almatica CNS subsidiary and globally. Solaxa eligible for $95M in aggregate milestone payments plus double-digit royalties.
  • University of California, Los Angeles (UCLA)coreStrategic or Co-development Partner · 28 March 2025Partnership with Dr. Susan Perlman at UCLA for registrational clinical trial of SLX-100 for SCA27B. Funded by $7.3M Congressionally Directed Medical Research Program grant.
  • National Ataxia FoundationcoreStrategic or Co-development Partner · 25 September 2024Sponsored research agreement including participation in NAF's Drug Development Collaborative, sponsorship of CRC-SCA natural history study expansion to include SCA27B, and sponsorship of free genetic testing program for SCA27B diagnosis.
  • Penn State College of Medicine / Penn State HealthcoreStrategic or Co-development Partner · 24 January 2022Clinical trial collaboration evaluating 4-aminopyridine for diagnosing peripheral nerve injury type. Dr. John Elfar's team at CORTS conducting NIH-funded study to determine whether nerves are severed or crushed in trauma patients.
  • University of RochestercoreStrategic or Co-development PartnerFounding scientific collaboration with Mark Noble, Ph.D., Professor of Biomedical Genetics and Neuroscience at University of Rochester, who serves as CSO and Co-Founder. Technology based on discoveries from his lab.
  • University of ArizonacoreStrategic or Co-development PartnerFounding scientific collaboration with John Elfar, M.D., MBA, Professor and Chair of Orthopedics at University of Arizona, who serves as scientific advisor. His research on 4-AP for nerve injury diagnosis underlies company technology.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Solaxa competitors and assessment

Company assessment

Direct peers

  • Acorda Therapeutics: Original developer of branded dalfampridine (Ampyra/4-AP) approved for MS walking impairment; the same active ingredient Solaxa is reformulating for SCA27B. Acorda's commercialization history underpins Solaxa's strategic playbook.
  • Reata Pharmaceuticals: Rare neurology-focused biopharma developing therapies for serious neurological diseases, now part of Biogen. Comparable in clinical-stage development and orphan disease commercialization.
  • Catalyst Pharmaceuticals: Specialty pharma focused on rare neurological and ophthalmic diseases with orphan-drug commercialization expertise. Comparable in targeting rare CNS indications with high unmet need.
  • Harmony Biosciences: CNS-focused commercial-stage company that licensed and commercialized a neurology asset (Wakix). Comparable in licensing-driven model and rare neurology commercialization.
  • Larimar Therapeutics: Clinical-stage biotech developing therapies for rare neurodegenerative diseases including Friedreich's ataxia. Direct comparator in rare ataxia/neurodegenerative space.

Emerging players

  • Stoke Therapeutics: Clinical-stage company targeting severe genetic neurological diseases using antisense oligonucleotide technology. Overlaps in rare neurology with similar clinical-stage profile.
  • Azafaros: Clinical-stage company developing treatments for rare lysosomal storage disorders with neurological involvement. Comparable as emerging rare neurology biotech.
  • Aquestive Therapeutics: Specialty pharma with reformulation expertise in CNS indications via proprietary drug delivery platforms. Comparable to Solaxa's reformulation-driven 505(b)(2) strategy for CNS.

Broad incumbents

  • Biohaven Pharmaceuticals: CNS-focused biopharma with broad neurology pipeline. Comparable as a CNS-focused specialty pharma that has successfully licensed and commercialized rare neurology assets.
  • Sage Therapeutics: CNS-focused biopharma developing therapies for neurological and psychiatric disorders. Comparable as a broader CNS biopharma with orphan-drug experience and licensing-driven commercialization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Solaxa social profiles

Digital presence

Solaxa compliance and trust

Trust signal

Compliance2 records

Solaxa financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Solaxa leadership team

Management profile

Number of profiles

Profiles6 records

Solaxa funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Solaxa M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solaxa

What does Solaxa do?

Solaxa develops proprietary aminopyridine-based drug candidates — most notably SLX-100, a reformulated dalfampridine (4-aminopyridine) — to detect and treat nerve dysfunction in rare neurodegenerative and traumatic nerve disorders such as spinocerebellar ataxia type 27B (SCA27B), hereditary ataxias, peripheral nerve injury, and chemotherapy-induced peripheral neuropathy. The company advances these candidates through FDA clinical and regulatory milestones and monetizes them via out-licensing to commercial partners rather than direct sales.

Is Solaxa a public or private company?

Solaxa is a private company. It is classified as venture growth investor backed and is currently operating.

When was Solaxa founded?

Solaxa was founded in 2021. It employs 1 to 10 people.

Where is Solaxa based?

Solaxa is headquartered in Bethesda, United States, in the North America region.

How does Solaxa make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are drug Development and Commercialization.

Who are Solaxa's main competitors?

Direct peers on record are Acorda Therapeutics, Reata Pharmaceuticals, Catalyst Pharmaceuticals, Harmony Biosciences and Larimar Therapeutics. Emerging players are Stoke Therapeutics, Azafaros and Aquestive Therapeutics. Broad incumbents are Biohaven Pharmaceuticals and Sage Therapeutics.

Does Solaxa have an API?

No public API is recorded for Solaxa.

What industry is Solaxa in?

Solaxa's product category is Rare Disease Neurology Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals